India Recombinant Protein Therapeutics Cdmo Market Size & Outlook
India recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
India recombinant protein therapeutics cdmo market highlights
- The India recombinant protein therapeutics cdmo market generated a revenue of USD 812.1 million in 2023 and is expected to reach USD 2,108.5 million by 2030.
- The India market is expected to grow at a CAGR of 14.6% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 812.1 million |
| Market revenue in 2030 | USD 2,108.5 million |
| Growth rate | 14.6% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, India accounted for 3.9% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,968.6 million by 2030.
Interferons was the largest segment with a revenue share of 21.45% in 2023. Horizon Databook has segmented the India recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
India is the most lucrative market among the developing nations. This can be attributed to the significant presence of WHO-cGMP-compliant facilities. Increasing government funding for R&D to accelerate new product development is expected to improve the number of new drugs in the country, promoting the demand for recombinant protein therapeutics CDMO in India.
However, new regulations have limited attention from many global companies. Owing to the falling percentage of outsourcing activities, the Indian government is taking initiatives and relaxing regulations so that it receives more outsourcing projects.
The Central Drugs Standard Control Organization (CDSCO) is an organization that is responsible for approving clinical trials in the country. This organization also monitors the quality of clinical trials in the country. The presence of such organizations in India is expected to improve clinical research in India and promote market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
India recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
India Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
